Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lannett’s primidone

Executive Summary

Philadelphia-based generic firm supplemental ANDA for anticonvulsant primidone, an AB-rated equivalent of Wyeth-Ayerst's Mysoline, approved Nov. 9. Approval is second for Lannett since it suspended operations in August 1991 to upgrade facilities and establish inventory and quality control procedures. Primidone will be available in 250 mg capsules for $310 per 1,000.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS023640

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel